Researchers developed the 24-hour dietary recall–plastic exposure (24DR-PE) tool to assess and quantify dietary plastic ...
BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and ...
Results from a phase 1/2 clinical trial of a novel stem cell treatment for cornea injuries found 14 patients treated and tracked for 18 months had a more than 90% success rate at restoring the ...
9h
Hosted on MSNMIRA Announces Approval of Important TestingMIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a clinical-stage pharmaceutical company that focuses on the development and commercialization of a new molecular synthetic ...
Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on ...
Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all ...
A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This ...
We reduced our fair value estimate to $15.50 per share from $27.20 to account for greater headwinds as a newly stand-alone company since its spinoff from Labcorp in 2023, which will weigh on revenue ...
A new computational tool allows researchers to understand how the diverse cell types of the human body are made during ...
A decade after scientists in The Picower Institute for Learning and Memory at MIT first began testing whether sensory stimulation of the brain's 40Hz "gamma" frequency rhythms could treat Alzheimer's ...
A new generation of therapeutics looks beyond simply reengineering the gut microbiome to exploiting multiple pathways for novel microbiome and microbial applications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results